File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Targeting tumor hypoxia in nasopharyngeal carcinoma

TitleTargeting tumor hypoxia in nasopharyngeal carcinoma
Authors
Issue Date2013
Citation
Head and Neck, 2013, v. 35 n. 1, p. 133-145 How to Cite?
AbstractBackground Nasopharyngeal carcinoma (NPC) is an endemic head and neck cancer in Southeast Asia. Although concurrent chemoradiotherapy generally results in good clinical response for early diseases, posttreatment relapse and distant metastasis are major causes for NPC deaths. There is an urgent need for more effective therapies for advanced NPC. Recent studies have demonstrated tumor hypoxia can be a therapeutic target in NPC. Methods A Medline review of articles published on clinical and preclinical studies targeting tumor hypoxia was performed. Results Studies published to date showed that tumor hypoxia is common in NPC and it is associated with disease progression and resistance to therapy. Several mechanisms have been proposed on the role of tumor hypoxia in NPC cell survival, angiogenesis, and metabolism. Studies reported by us and by others have demonstrated the therapeutic potential of targeting tumor hypoxia in NPC. Conclusions Cumulative studies indicate that targeting tumor hypoxia could be an effective approach for NPC treatment. © 2011 Wiley Periodicals, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/194372
ISSN
2015 Impact Factor: 2.76
2015 SCImago Journal Rankings: 1.233
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHong, B-
dc.contributor.authorLui, VWY-
dc.contributor.authorHashiguchi, M-
dc.contributor.authorHui, EP-
dc.contributor.authorChan, AT-C-
dc.date.accessioned2014-01-30T03:32:30Z-
dc.date.available2014-01-30T03:32:30Z-
dc.date.issued2013-
dc.identifier.citationHead and Neck, 2013, v. 35 n. 1, p. 133-145-
dc.identifier.issn1043-3074-
dc.identifier.urihttp://hdl.handle.net/10722/194372-
dc.description.abstractBackground Nasopharyngeal carcinoma (NPC) is an endemic head and neck cancer in Southeast Asia. Although concurrent chemoradiotherapy generally results in good clinical response for early diseases, posttreatment relapse and distant metastasis are major causes for NPC deaths. There is an urgent need for more effective therapies for advanced NPC. Recent studies have demonstrated tumor hypoxia can be a therapeutic target in NPC. Methods A Medline review of articles published on clinical and preclinical studies targeting tumor hypoxia was performed. Results Studies published to date showed that tumor hypoxia is common in NPC and it is associated with disease progression and resistance to therapy. Several mechanisms have been proposed on the role of tumor hypoxia in NPC cell survival, angiogenesis, and metabolism. Studies reported by us and by others have demonstrated the therapeutic potential of targeting tumor hypoxia in NPC. Conclusions Cumulative studies indicate that targeting tumor hypoxia could be an effective approach for NPC treatment. © 2011 Wiley Periodicals, Inc.-
dc.languageeng-
dc.relation.ispartofHead and Neck-
dc.titleTargeting tumor hypoxia in nasopharyngeal carcinoma-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/hed.21877-
dc.identifier.pmid22106024-
dc.identifier.scopuseid_2-s2.0-84871233667-
dc.identifier.volume35-
dc.identifier.issue1-
dc.identifier.spage133-
dc.identifier.epage145-
dc.identifier.isiWOS:000312551300030-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats